Kinetic Degradation Study of Dapagliflozin Coupled with UHPLC Separation in the Presence of Major Degradation Product and Metformin
- 101 Downloads
A novel ultra-performance liquid chromatography with UV detector technique was established for simultaneous determination of two antidiabetic drugs, dapagliflozin (DAPA) and metformin (MET), followed by a stress degradation study. Main degradation product was chromatographically separated and precisely characterized via LC-MS/MS. Chromatographic separation done on a Symmetry® Acclaim™ RSLC 120 C18 column (100 mm, 2.1 mm, 2.2 µm), column temperature was maintained at 60 °C. Mobile phase was a mixture of potassium dihydrogen phosphate buffer, pH (3.5)—acetonitrile (50:50, v/v) at flow rate of 0.4 mL/min. The method has displayed an adequate detection at concentration ranges of 1–50 µg/mL for dapagliflozin propanediol monohydrate and 0.5–100 µg/mL for metformin hydrochloride. DAPA was then exposed to different stress conditions include alkaline, acidic, oxidative and ultraviolet light. A study of the degradation kinetics in alkaline medium for DAPA has proved that the degradation follows a pseudo-first-order reaction. The proposed method was effectively applied for the analysis of laboratory prepared mixtures as well as a combined pharmaceutical formulation with 1:200 ratio of DAPA: MET. No significant difference was found regarding accuracy and precision upon statistical comparison between the obtained results and those of the reported method. Validation was conducted in compliance with the ICH guidelines proving that method is selective, linear, precise and accurate. The simplicity and sensitivity of this method allows its use in the quality control tests of the two cited drugs.
KeywordsDapagliflozin Metformin Degradation kinetics SGLT2 Xigduo XR Stability study HPLC–UV UHPLC–UV
This study was self-funded, no fund is received.
Compliance with ethical standards
Conflict of interest
No conflict of interest of any kind.
Research involving human or animal participants
This article does not contain any studies with human participants or animals performed by any of the authors.
- 3.Jani B, Shah K, Kapupara P (2015) Int J Res Dev Pharm L Sci 4:1569–1576Google Scholar
- 4.Jani B, Shah V, Kapupara P (2015) J Bioequivalence Stud 1:1–7Google Scholar
- 5.Yunoos M, Sankar G (2015) Asian J Pharm Clin Res 8:320–326Google Scholar
- 6.Shyamala B, Nidhi M, Kavitha, Pooja, Sharma J (2015) Am J Biol Pharm Res 2:109–113Google Scholar
- 7.Deepan T (2017) Eur J Appl Sci 9:189–199Google Scholar
- 8.Chitra K, Eswaraiah C, Rao M (2015) J Chem Pharm Res 7:45–49Google Scholar
- 9.Sanagapati M, Dhanalakshmi K, Reddy G, Sreenivasa S (2014) J Adv Pharm Educ Res 4:350–353Google Scholar
- 10.Manasa S, Dhanalakshmi K, Reddy G, Kavitha B (2014) Int J Pharm Sci Rev Res 27:270–272Google Scholar
- 11.Manasa S, Dhanalakshmi K, Nagarjunareddy G, Sreenivasa S (2014) IJPSR 5:5394–5397Google Scholar
- 12.Sanagapati M, Dhanalakshmi K, Reddy G, Sreenivasa S (2014) Int J Pharm Sci Drug Res 6:250–252Google Scholar
- 15.Sengupta P, Bhaumik U, Ghosh A, Sarkar A, Chromatographia, 2009, 69, 1243–1250Google Scholar
- 16.Elbagary R, Elkady E, Ayoub B (2011) Int J Biomed Sci 7:201–208Google Scholar
- 19.Ali M, Rafiuddin S, Ghori M, Khatri A, Chromatographia, 2008, 67, 517–525Google Scholar
- 21.Elbagary R, Elkady E, Ayoub B, Talanta, 2011, 85, 673–680Google Scholar
- 25.Ghassempour M, Ahmadi S, Ebrahimi, Aboul-Enein H, Chromatographia, 2006, 64, 101–104Google Scholar
- 26.Elbagary R, Elkady E, Ayoub B (2011) Int J Biomed Sci 7:62–69Google Scholar
- 28.Pawar S, Meshram G, Phadke M, Chromatographia, 2008, 68, 1063–1066Google Scholar
- 31.Mowaka S, Elkady E, Elmazar M, Ayoub B, Microchem J, 2017, 130, 360–365Google Scholar
- 35.Miller JN, Miller JC, Statistics and chemometrics for analytical chemistry, 5th edn, Pearson Education Limited, Harlow, 2005Google Scholar
- 36.ICH Harmonized Tripartite Guideline, Validation of Analytical Procedures: Text and Methodology, Q2 (R1), Current step 4 version, Parent guidelines on Methodology, 1996, incorporated in November 2005Google Scholar
- 37.ICH Harmonised Tripartite Guidelines, Q1A (R2) Stability Testing of New Drug Substances and Products, 2003Google Scholar